
François Vergez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2424788/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discovery, 2017, 7, 716-735.	9.4	582
2	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica, 2011, 96, 1792-1798.	3.5	164
3	Assessment of tumor-infiltrating TCRV γ 9V δ 2 γŕ lymphocyte abundance by deconvolution of human cancers microarrays. Oncolmmunology, 2017, 6, e1284723.	4.6	134
4	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood, 2016, 127, 882-892.	1.4	108
5	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood, 2013, 121, 2618-2626.	1.4	100
6	The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. Cell Reports, 2014, 7, 1815-1823.	6.4	86
7	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.	12.8	84
8	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 483-497.	8.5	68
9	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 131-142.	2.2	57
10	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	1.4	53
11	Antileukemic Activity of 2-Deoxy- <scp>d</scp> -Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with <i>FLT3-ITD</i> or <i>c-KIT</i> Mutations. Molecular Cancer Therapeutics, 2015, 14, 2364-2373.	4.1	52
12	Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica, 2018, 103, 988-998.	3.5	49
13	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1204-1223.	13.2	42
14	Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2020, 10, 1544-1565.	9.4	39
15	Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. Nature Communications, 2021, 12, 422.	12.8	36
16	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. Haematologica, 2017, 102, 1718-1726.	3.5	32
17	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget, 2011, 2, 850-861.	1.8	29
18	Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. Leukemia Research, 2015, 39, 818-821.	0.8	24

François Vergez

#	Article	IF	CITATIONS
19	Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia. Cancers, 2021, 13, 629.	3.7	23
20	Impact of obesity in favorableâ€risk <scp>AML</scp> patients receiving intensive chemotherapy. American Journal of Hematology, 2016, 91, 193-198.	4.1	22
21	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget, 2015, 6, 38061-38078.	1.8	20
22	Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 855-862.	1.3	16
23	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers, 2020, 12, 1725.	3.7	13
24	Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study. Cancers, 2020, 12, 773.	3.7	11
25	Canine Reference Intervals for Coagulation Markers Using the STA Satellite® and the STA-R Evolution® Analyzers. Journal of Veterinary Diagnostic Investigation, 2010, 22, 690-695.	1.1	10
26	Rituximab–cyclophosphamideâ€dexamethasone is highly effective in patients with monoclonal <scp>I</scp> g depositâ€related glomerulopathy and indolent nonâ€ <scp>H</scp> odgkin lymphomas. American Journal of Hematology, 2014, 89, 969-973.	4.1	9
27	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget, 2016, 7, 85937-85947.	1.8	9
28	Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. Cancers, 2020, 12, 2044.	3.7	8
29	Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells. Blood Cancer Journal, 2017, 7, 636.	6.2	7
30	CD34+CD38â^'CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. Cancers, 2020, 12, 1174.	3.7	7
31	Major rise of a chronic lymphoid leukemia clone during the course of COVIDâ€19. International Journal of Laboratory Hematology, 2021, 43, e82-e83.	1.3	7
32	Genomic landscape of hyperleukocytic acute myeloid leukemia. Blood Cancer Journal, 2022, 12, 4.	6.2	7
33	Bendamustine plus rituximab for indolent Bâ€cell lymphoma of renal significance. American Journal of Hematology, 2018, 93, 356-362.	4.1	6
34	CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome. Blood Advances, 2022, 6, 1813-1825.	5.2	6
35	From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review. Diagnostics, 2021, 11, 1982.	2.6	6
36	Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry. British Journal of Haematology, 2022, 196, 1175-1183.	2.5	6

François Vergez

#	Article	IF	CITATIONS
37	Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis. Clinical and Experimental Nephrology, 2017, 21, 781-786.	1.6	3
38	Large granular lymphocytosis during quizartinib therapy. British Journal of Haematology, 2020, 189, 7-7.	2.5	2
39	Class I Phosphoinositide 3-Kinases in Normal and Pathologic Hematopoietic Cells. Current Topics in Microbiology and Immunology, 2012, 362, 163-184.	1.1	2
40	Spectrum of Kidney Disorders Associated with T-Cell Immunoclones. Journal of Clinical Medicine, 2022, 11, 604.	2.4	2
41	Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis. Leukemia Research, 2018, 75, 7-10.	0.8	1
42	Identification of circulating regulatory T lymphocytes with membrane markers — a new multiparameter flow cytometry protocol. Folia Histochemica Et Cytobiologica, 2021, 59, 75-85.	1.5	1
43	Eyeâ€catching spindleâ€shaped mast cells without sinister significance. British Journal of Haematology, 2021, 192, 798-798.	2.5	0
44	Genomics of Hyperleukocytic Acute Myeloid Leukemia. Blood, 2021, 138, 1294-1294.	1.4	0
45	"Accelerated phase―chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies. Hematological Oncology, 2022, 40, 805-808.	1.7	0